Quanterix Acquires EMISSION to Enhance Biomarker Detection Technology and Diagnostic Capabilities

Quanterix Expands Technological Horizons with EMISSION Acquisition

Quanterix Corporation, a prominent entity in ultrasensitive biomarker detection, announces its strategic acquisition of EMISSION Inc. for $10 million, with the potential for additional payments reaching $60 million based on performance and technical achievements. The deal is set to close in January 2025 and marks a significant step in Quanterix's aim to enhance its technological capabilities, particularly with its upcoming Simoa platform. This acquisition is a pivotal move as Quanterix seeks to broaden its portfolio in biomarker detection, specifically in the areas of multi-plex and multi-omic functions.

The integration of EMISSION’s proprietary bead technology into Quanterix’s operations is expected to bolster the company’s offerings significantly. EMISSION specializes in the production of highly-uniform dye-encapsulating magnetic beads that are crucial for low and mid-plex assays. This technology is already validated on the Simoa platform, allowing Quanterix not only to secure critical materials for its next-generation diagnostic tools but also to provide original equipment manufacturer (OEM) beads to third-party customers. Quanterix’s CEO, Masoud Toloue, underscores the importance of controlling core components as the company prepares to expand its capabilities and product line.

Van Chandler, CEO of EMISSION, expresses excitement about joining forces with Quanterix, citing a shared vision for advancing their high-quality bead technology across laboratories. This partnership is expected to be accretive to Quanterix’s revenue and gross margins starting in 2026, further solidifying the company’s leadership position in the diagnostic market. With a proven track record in early biomarker detection across multiple fields such as neurology, oncology, and infectious diseases, Quanterix aims to leverage this acquisition to enhance its innovative product offerings and support groundbreaking research.

The acquisition of EMISSION signifies Quanterix's commitment to advancing the field of biomarker detection through strategic technological enhancements. As the company prepares to integrate EMISSION's capabilities, it provides a glimpse into its future direction and the potential for expanded applications in diagnostics.

In summary, Quanterix's acquisition of EMISSION not only strengthens its technological foundation but also enhances its competitive edge in the rapidly evolving diagnostics landscape. This strategic move emphasizes the importance of innovation and collaboration in delivering high-quality diagnostic solutions.